Furthermore, the expression of PD-L1 increases after sorafenib treatment, and the combination of AMD3100 and the anti-PD-1 antibody significantly delays tumor growth and metastasis by promoting the infiltration of activated CTLs into tumors [117]. The gene discussed is PDCD1; the disease is neoplasm.